High throughput S. cerevisiae HAM, GWA & QT/QTL architecture

描述（由申请人提供）： 广泛的长期目标：在具体目标1中，我们将对另外88个遗传多样性的S.酿酒酵母菌株，使此类菌株的总数达到96个，其将用作特异性目的2-4的基础。在特定目标2中，我们将使用单倍体关联作图来鉴定控制对5-氟嘧啶（临床使用的抗癌和/或抗真菌药物）和膜应激物（其中许多是临床使用的抗真菌药物）耐药性的候选药物遗传学QTG。在具体目标3中，我们将在4，560个成员的F1群体中使用全基因组关联来鉴定候选药物遗传学QTG。同时，我们将在500和600个成员F2群体中进行药物遗传QTL定位。单倍体关联作图和全基因组关联分析可以在众多QTL中识别出候选QTL。类似地，QTL作图将鉴定许多单倍体关联作图和全基因组关联真/假关联和假阴性。最后，在具体目标4中，我们将使用高通量F1 RHA来测试候选QTG，评估上位性与遗传异质性，并确定F1群体范围内的QT/QTL结构。

DESCRIPTION (provided by applicant): Broad long-term objectives: In Specific Aim 1, we will sequence and annotate the genomes of an additional 88 genetically diverse S. cerevisiae strains, bringing the total of such strains to 96, which will serve as the bases for Specific Aims 2-4. In Specific Aim 2, we will use haploid association mapping to identify candidate pharmacogenetic QTGs controlling resistance to 5- fluoropyrimidines, which are clinically used anti-cancer and/or antifungal agents, and membrane stressors, many of which are clinically used antifungal agents. In Specific Aim 3, we will use genome wide association, in a 4,560 member F1 population, to identify candidate pharmacogenetic QTGs. In parallel, we will QTL map, in 500 and 600 member F2 populations, pharmacogenetic QTLs. The haploid association mapping and genome wide association will identify candidate QTGs in many QTLs. Similarly, the QTL mapping will identify many haploid association mapping and genome wide association true/false associations and false negatives. Finally, in Specific Aim 4, we will use high throughput F1 RHA to test candidate QTGs, evaluate epistasis vs. genetic heterogeneity and determine F1 population-wide QT/QTL architecture.